Experimental prescription, rising resistance: the alarming misuse of ceftazidime-avibactam in healthcare systems
Abstract
No abstract
1. Zhang S, Liao X, Ding T, Ahn J. Role of β-lactamase Inhibitors as potentiators in antimicrobial chemotherapy targeting Gram-negative bacteria. Antibiotics (Basel) 2024; 15; 13: 260.
2. Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis 2019; 69(Suppl 7):S565-S575.
3. Veeraraghavan B, Devi Bakthavatchalam Y, Diana Sahni R, Malhotra S, Bansal N, Walia K, et al. Loss of exclusivity of ceftazidime/avibactam in low- and middle-income countries: a test for antibiotic stewardship practice. Lancet Reg Health Southeast Asia 2023; 15:100225.
4. Ghanbarinasab F, Haeili M, Nasiri Ghanati S, Moghimi M, Mohaddeseh Moghimi. High prevalence of OXA-48-like and NDM carbapenemases among carbapenem resistant Klebsiella pneumoniae of clinical origin from Iran. Iran J Microbiol 2023;15:609-615.
5. Nikbin VS, Haj Agha Gholizadeh Khiavi E, Dehghani-Latani M, Hosseinzadeh M, Shirzadi M, Pourajam S, et al. Failure of ceftazidime/avibactam experimental therapy in the treatment of Klebsiella pneumoniae ST11 co-producing NDM-1 and OXA-48 carbapenemases infection. Eur J Clin Microbiol Infect Dis 2024;43:2023-2027.
2. Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis 2019; 69(Suppl 7):S565-S575.
3. Veeraraghavan B, Devi Bakthavatchalam Y, Diana Sahni R, Malhotra S, Bansal N, Walia K, et al. Loss of exclusivity of ceftazidime/avibactam in low- and middle-income countries: a test for antibiotic stewardship practice. Lancet Reg Health Southeast Asia 2023; 15:100225.
4. Ghanbarinasab F, Haeili M, Nasiri Ghanati S, Moghimi M, Mohaddeseh Moghimi. High prevalence of OXA-48-like and NDM carbapenemases among carbapenem resistant Klebsiella pneumoniae of clinical origin from Iran. Iran J Microbiol 2023;15:609-615.
5. Nikbin VS, Haj Agha Gholizadeh Khiavi E, Dehghani-Latani M, Hosseinzadeh M, Shirzadi M, Pourajam S, et al. Failure of ceftazidime/avibactam experimental therapy in the treatment of Klebsiella pneumoniae ST11 co-producing NDM-1 and OXA-48 carbapenemases infection. Eur J Clin Microbiol Infect Dis 2024;43:2023-2027.
| Files | ||
| Issue | Vol 16 No 6 (2024) | |
| Section | Letter to the Editor | |
| DOI | https://doi.org/10.18502/ijm.v16i6.17243 | |
| Keywords | ||
| No keywords | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Akbari M, Giske C, Solgi H. Experimental prescription, rising resistance: the alarming misuse of ceftazidime-avibactam in healthcare systems. Iran J Microbiol. 2024;16(6):720-721.
